We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$123M
Cap. Flow %
-3.14%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Technology 0.53%
4 Real Estate 0.1%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
V icon
101
Visa
V
$701B
$698K 0.02%
2,500
– –
PYPL icon
102
PayPal
PYPL
$50.3B
$670K 0.02%
10,000
+5,000
+100% +$307K
CFLT
103
DELISTED
Confluent
CFLT
$580K 0.01%
19,000
– –
CRBU icon
104
Caribou Biosciences
CRBU
$146M
$541K 0.01%
105,347
– –
CYCN icon
105
Cyclerion Therapeutics
CYCN
$15.2M
$445K 0.01%
138,955
– –
CWAN
106
DELISTED
Clearwater Analytics
CWAN
$442K 0.01%
25,000
+5,000
+25% +$92.9K
DLO icon
107
dLocal
DLO
$4.29B
$441K 0.01%
30,000
+10,000
+50% +$167K
HIPO icon
108
Hippo Holdings
HIPO
$777M
$438K 0.01%
24,000
– –
TSLA icon
109
Tesla
TSLA
$1.18T
$352K 0.01%
+2,000
New +$391K
GOSS icon
110
CALL
Gossamer Bio
GOSS
$101M
$244K 0.01%
207,000
– –
INKT icon
111
MiNK Therapeutics
INKT
$51.7M
$1.74K ﹤0.01%
192
– –
ARGX icon
112
argenx
ARGX
$55.2B
– –
-116,388
Closed -$44.3M
BZ icon
113
Kanzhun
BZ
$7.19B
– –
-100,000
Closed -$1.66M
CRIS icon
114
Curis
CRIS
$9.71M
– –
-5,250
Closed -$1.34M
FOLD
115
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-2,500,000
Closed -$35.5M
IMA
116
ImageneBio Inc
IMA
$63.4M
– –
-83,293
Closed -$1.97M
ITOS
117
DELISTED
iTeos Therapeutics
ITOS
– –
-400,000
Closed -$4.38M
LLY icon
118
Eli Lilly
LLY
$1.08T
– –
-1,000
Closed -$583K
NTRA icon
119
Natera
NTRA
$36.4B
– –
-200,000
Closed -$12.5M
RELY icon
120
Remitly
RELY
$4.9B
– –
-25,000
Closed -$486K
REPL icon
121
Replimune Group
REPL
$454M
– –
-500,000
Closed -$4.21M
ROIV icon
122
Roivant Sciences
ROIV
$23.6B
– –
-1,000,000
Closed -$11.2M
SDGR icon
123
Schrodinger
SDGR
$1.13B
– –
-300,000
Closed -$10.7M
SNTI icon
124
Senti Biosciences Holdings
SNTI
$10.8M
– –
-5,556
Closed -$37K
XLO icon
125
Xilio Therapeutics
XLO
$59.8M
– –
-32,143
Closed -$248K
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group withdrew a net $123M in Q1 2024, closing 20 positions and reducing 17 holdings. Its most notable exit was argenx, an estimated $44.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Crinetics Pharmaceuticals worth $65.1M.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.